Neonatal genome-wide methylation patterns in relation to birth weight in the Norwegian mother and child cohort by Engel, Stephanie M. et al.
Original Contribution
Neonatal Genome-Wide Methylation Patterns in Relation to Birth Weight in the
Norwegian Mother and Child Cohort
Stephanie M. Engel*, Bonnie R. Joubert, Michael C. Wu, Andrew F. Olshan, Siri E. Håberg,
Per Magne Ueland, Wenche Nystad, Roy M. Nilsen, Stein Emil Vollset, Shyamal D. Peddada,
and Stephanie J. London*
* Correspondence to Dr. Stephanie M. Engel, Campus Box 7435, Department of Epidemiology, Gillings School of Global Public Health, University
of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7435 (e-mail: stephanie.engel@unc.edu); or Dr. Stephanie London, National Institute of
Environmental Health Sciences, PO Box 12233, MD A3-05, Research Triangle Park, NC 27709 (e-mail: london2@niehs.nih.gov).
Initially submitted July 25, 2013; accepted for publication December 18, 2013.
Although epigenetic regulation plays a critical role in embryonic development, few studies have examined the
relationship of epigenome-wide methylation with fetal growth. Using the Infinium HumanMethylation450 BeadChip
(Illumina, Inc., San Diego, California) in a substudy of 1,046 infants from the Norwegian Mother and Child Cohort
Study (MoBa) enrolled between 1999 and 2008, we examined epigenome-wide cord blood DNA methylation in re-
lation to birth weight. In multivariable-adjusted robust linear regressionmodels, we identified differential methylation
at 19 cytosine-guanine dinucleotides (CpGs) associated with either decreased (AT-rich interactive domain 5B
(MRF1-like) (ARID5B), 2 CpGs) or increased (x-ray repair complementing defective repair in Chinese hamster
cells 3 (XRCC3), 4 CpGs) birth weight. ARID5B knockout mice have less adipose tissue and significantly lower
weight in the postnatal period. XRCC3 plays a key role in the maintenance of chromosome stability and the repair
ofDNAdamage.Although thereare fewer dataon theother implicatedgenes,manyof thesegeneshavebeenshown
to have roles in developmental processes. This constitutes the largest andmost robust study of birth weight using an
epigenome-wide methylation platform and offers potential insights into epigenetic mechanisms of fetal growth.
birth weight; cord blood; epigenetics; methylation; MoBa; Norwegian Mother and Child Cohort Study
Abbreviations: CpG, cytosine-guanine dinucleotide; MoBa, Norwegian Mother and Child Cohort Study.
Epigenetic pathways regulate fetal development by con-
trolling the expression of genes (1), facilitating both precisely
timed and highly coordinated developmental processes (2).
The most well-characterized of these epigenetic pathways is
DNA methylation, the addition of a methyl group usually to
cytosines in cytosine-guanine dinucleotide (CpG) sites (3).
The relationship between CpG methylation and gene expres-
sion is complex and incompletely understood. Recent studies
indicate that methylation at promoter and island regions tends
to result in gene silencing; however, methylation in gene
bodies tends to enhance gene expression (4–6). Loss of meth-
ylation at speciﬁc imprinted regions leads to serious growth-
related congenital anomalies, such as Beckwith-Wiedemann
and Silver-Russell syndromes (7, 8). However, there are
limited data in humans on the role of more modest variability
in DNAmethylation status in the growth and development of
the fetus.
Although some portion of epigenetic lability is under ge-
netic control (9), epigenomic consequences of exposures
experienced in utero (10–12) have been documented in hu-
mans. For example, maternal depression (13) and smoking
during pregnancy (11), both of which are predictors of
reduced birth weight, have been associated with altered meth-
ylation proﬁles in either gene-speciﬁc (13) or epigenome-
scale (11) investigations. In particular, Joubert et al. (11)
identiﬁed signiﬁcant associations between maternal smoking
in pregnancy and differential methylation in genes involved
in fundamental developmental processes. Together, these
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results support the hypothesis that birth weight, and/or path-
ways leading to birth weight, may be affected by differences
in methylation.
A few studies have begun to examine the associations of
gene-speciﬁc methylation with birth weight. Targeted inves-
tigations have involved genes hypothesized to play key roles
in growth (e.g., insulinlike growth factor 2), and/or that may
be sensitive to famine exposure in pregnancy (GNAS anti-
sense RNA 1 (GNASAS), INS-IGF2 readthrough (INS-IGF2),
and leptin (LEP)). However, studies have thus far not provided
consistent evidence of an association with birth weight in hu-
mans (14–16). Recently, 2 epigenome-scale investigations of
methylation in relation to birth weight have been published, al-
though both had relatively small study populations and lacked
adjustment for potentially important confounders. None of the
principal ﬁndings in these studies overlap (17, 18).
We undertook an investigation of the relationship between
CpG-speciﬁc cord blood DNA methylation and birth weight
using the InﬁniumHumanMethylation450 BeadChip (Illumina,
Inc., San Diego, California) among 1,046 newborns from the
Norwegian Mother and Child Cohort Study (MoBa).
METHODS
Study population
MoBa enrolled more than 100,000 women between 1999
and 2008. Study design and selection characteristics have
been described in detail elsewhere (19, 20). Women were in-
vited by mail to participate prior to their routine ultrasonog-
raphy examinations at their local hospitals, usually scheduled
at approximately 18 weeks’ gestation. Participation rates var-
ied by study year (20) but averaged 38.5%. Exposure-related
information was collected by questionnaire at the ﬁrst enroll-
ment visit and then again at approximately 30 weeks’ gesta-
tion. Information on dietary folate intake was collected using
a semiquantitative food frequency questionnaire returned by
the mothers at approximately 18–22 gestational weeks. The
food frequency questionnaire consisted of 263 questions
about 255 food items and was designed to capture dietary
habits and intakes of dietary supplements during the ﬁrst
4–5 months of pregnancy (21, 22). Methods regarding calcu-
lation of nutrient and energy intakes have been previously de-
scribed (21, 22). Brieﬂy, nutrient and energy intakes were
calculated using FoodCalc (http://www.ibt.ku.dk/jesper/
FoodCalc/Default.htm) and the Norwegian Food Composi-
tion Table (23).We adjusted for folate intake from foods.Mea-
surement of plasma folate status was obtained from maternal
blood samples collected at the enrollment visit (at approxi-
mately 18 weeks’ gestation). Plasma folate was measured
using a microbiological assay with a chloramphenicol-resistant
strain of Lactobacillus casei (24). The assay determines bio-
logically active folate species, predominantly 5-methyl-
tetrahydrofolate, and has a coefﬁcient of variation of 4%
within day and 5% between days at population median con-
centration (24). The Medical Birth Registry of Norway re-
ceives mandatory information on all deliveries at hospitals
using a standardized birth notiﬁcation form (25). This form
includes demographic information about the mother and fa-
ther, information about the mother’s health before and during
pregnancy, including chronic diseases and pregnancy com-
plications, and information on delivery characteristics.
Within MoBa, a nested case-cohort subset was established
to examine prenatal risk factors for asthma at 3 years of age
(26), which included 507 singleton asthma cases and a refer-
ence population of 1,455 singletons randomly selected from
the MoBa population with 3-year follow-up data available.
The current study is based on the subset of these singletons
for whom cord blood and valid methylation data and data on
covariates relevant to analysis of birth weight were available
(n = 1,046) (11). This study was approved by the University
of North Carolina Chapel Hill Ofﬁce of Human Research
Ethics (Chapel Hill, North Carolina).
DNA methylation
DNAmethylation at 485,577 cytosine positions (CpG sites)
was measured in cord blood from the MoBa samples using the
Inﬁnium HumanMethylation450 BeadChip (27, 28). Bisulﬁte
conversion was performed using the EZ-96 DNA methylation
kit (Zymo Research Corporation, Irvine, California) according
tomanufacturer instructions andwas checked permethods pre-
viously described (27). For each sample, the methylation level
at each CpG was calculated in Illumina’s GenomeStudio
methylation module as β = intensity of the methylated allele
(M) / (intensity of the unmethylated allele (U) + intensity of
the methylated allele (M) + 100) (27). The β values were logit
transformed to obtain the log ratio [log ratio = log(β / 1− β)],
which may have better statistical properties than the β values
(29). Bisulﬁte conversion and DNA methylation were per-
formed at Illumina, Inc. (San Diego, California) within a sin-
gle month according to methods previously described (27).
Quality control has been previously described (11). Brieﬂy,
duplicate samples and control samples were included on each
plate in a blinded fashion, and a series of methylation controls
(10%, 35%, 60%, and 85% methylated) was included on the
ﬁrst and last plates. The distribution of birth weight by ana-
lytical plate was similar, with overlapping means and inter-
quartile ranges (data not shown). After adjustment for the
covariates’ associations, birth weight was not found to be dif-
ferent across DNA plates (Kruskal-Wallis P = 0.30). Detection
P values and multidimensional scaling were used to identify
erroneous samples, and CpGs were excluded on the basis
of missing data and genomic position. After quality control
procedures, 1,068 subjects and 485,492 CpGs, including X
and Y probes, were available for analysis.
Statistical analysis of birth weight
We excluded 14 in vitro fertilization subjects and 9 sub-
jects with missing covariates, leaving 1,046 subjects for anal-
ysis. We conducted an epigenome-wide analysis in which we
evaluated the association between birth weight and methyla-
tion in cord blood at each of the 485,492 CpG sites, 1 at a
time. Speciﬁcally, using birth weight as the dependent vari-
able and the log ratio of methylation as the predictor, we ap-
plied robust linear regression with sandwich-based estimators
of the covariance to accommodate potential outliers and het-
eroscedasticity (30). We adjusted for child sex, maternal
plasma cotinine (11), parity, maternal age, dietary folate
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not including supplements (24), asthma, gestational age at
delivery, gestational age at delivery squared, preeclampsia,
season of birth, and leukocyte cell–type proportions (31,
32) as potential confounders. Analyses using plasma instead
of dietary folate yielded similar results. Given the number of
statistical tests conducted, we report only CpGs that are sig-
niﬁcant after Bonferroni correction (485,492 statistical tests,
P < 1.03 × 10−7).
RESULTS
The majority of the mothers were between the ages of 25
and 34 years. Approximately 40% were nulliparous. The dis-
tribution of maternal plasma cotinine levels suggested that
approximately 13% were active smokers (plasma cotinine
>56.8 nmol/L (33)) at the time of blood collection, which oc-
curred at approximately 18 weeks’ gestation. The vast major-
ity of births occurred at term and were of a healthy birth
weight (≥2,500 g). In total, 54% of the infants were boys.
As described above (26), this cohort was designed to over-
represent asthma at 3 years, which accounted for approxi-
mately 33% of this study population (Table 1).
For the multivariable analysis of differential DNA methyl-
ation in relation to birth weight, we identiﬁed 19 CpGs that
reached Bonferonni signiﬁcance (P < 1.03 × 10−7) (Table 2,
Web Figure 1 available at http://aje.oxfordjournals.org/). Of
these, 13 were within genes and 6 were within intergenic re-
gions. CpGs associated with birth weight were AT-rich interac-
tion domain 5B (MRF1-like) (ARID5B) (2 CpGs); Kruppel-like
factor 9 (KLF9); x-ray repair complementing defective repair
in Chinese hamster cells 3 (XRCC3) (4 CpGs); phosphat
idylethanolamine-binding protein 4 (PEBP4); sema domain,
immunoglobulin domain, transmembrane domain, and short
cytoplasmic domain, (semaphorin) 4C (SEMA4C); spondin
2, extracellular matrix protein (SPON2); ubiquitin-like with
PHD and ring ﬁnger domains 1 (UHRF1); ankyrin repeat
domain 11 (ANKRD11); and major facilitator superfamily
domain containing 10 (MFSD10). The distributions of meth-
ylation values were transformed to approximate a normal dis-
tribution. Thus, the interpretation of the magnitude of the
difference in birth weight in relation to methylation increases
is as follows. For ARID5B, for each 1-logit increase in meth-
ylation of cg25953130 or cg02863179, birth weight was
lower by 371 g or 341 g, respectively (Table 2, Figure 1). For
XRCC3, for each 1-logit increase in methylation at cg021941
29, birth weight was higher by approximately 727 g (Table 2,
Figure 2). These models were adjusted for multiple con-
founders, including the estimated leukocyte cell–type pro-
portions of each sample (31, 32). For the remaining probes
found to be signiﬁcant in Table 2, illustrations of the relation-
ship between the untransformed methylation β value in rela-
tion to the birth weight residual after adjustment for important
confounders can be found in Web Figure 2.
We conducted a sensitivity analysis in which we adjusted
for caffeinated beverage intake in early pregnancy, maternal
prepregnancy body mass index (weight (kg)/height (m)2),
and maternal weight gain up until her completion of the third-
trimester questionnaire. Inclusion of these covariates resulted
in the loss of 128 participants. Adjustment for these addi-
tional covariates had little impact on the overall results when
compared with a model of the same sample size with those
covariates excluded (Web Figure 3A), although the following
probes were no longer signiﬁcant with this reduced sample
size, which was likely primarily due to a loss of power: cg20
076442, cg25124943, cg00605777, cg23127323, cg25162
533, cg23369670, cg23237276, cg05993265, and cg24693
803. Of the probes that remained signiﬁcant, themagnitude of
the regression coefﬁcient in all cases preserved direction (in-
crease or decrease in birth weight), with only small changes
in magnitude (mean change = 6.5%). In addition, when we
adjusted for measured plasma folate instead of dietary folate,
there was no substantial change in the estimated P values
(Web Figure 3B).
It is not yet clear how appropriate the available methods for
correcting for leukocyte cell–type proportions (31) are in the
setting of cord blood methylation, given that reference data
sets are available for only adult peripheral blood (32). There-
fore, we conducted analyses with and without this adjustment
factor (Table 2). In these models, 22 CpG probes were signiﬁ-
cant at a Bonferroni-corrected threshold (Web Table 1). How-
ever, the CpGs did not overlap perfectly with those that were
Table 1. Characteristics of 1,046 Subjects in the Norwegian Mother
and Child Cohort Study, 1999–2008
Characteristic No. %
Maternal age, years
15–24 130 12.4
25–29 406 38.8
30–34 384 36.7
≥35 126 12.0
Parity
0 425 40.6
1 432 41.3
≥2 189 18.1
Prenatal plasma cotinine, nmol/L
Undetectable 725 69.3
>0–56.8 188 18.0
56.9–388 68 6.5
≥389 65 6.2
Gestational age at delivery, weeks
<32 (<224 days) 1 0.1
32–36 (224–258 days) 36 3.4
37–41 (259–293 days) 926 88.5
≥42 (≥294 days) 83 7.9
Infant birth weight, g
<2,500 20 1.9
2,500–3,999 770 73.6
≥4,000 256 24.5
Infant sex
Male 562 53.7
Female 484 46.3
Asthma at age 3 years 349 33.4
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signiﬁcant after adjustment for cell type. Among the 19 probes
that were signiﬁcant in models adjusted for cell-type propor-
tions, 8 CpGs remained signiﬁcant without adjustment for
cell type (Table 2). Interestingly, associations with all of the
XRCC3 CpGs were signiﬁcant only in the models with cell-
type adjustment.
DISCUSSION
In this analysis of a homogeneous Norwegian population,
we report signiﬁcant associations between CpGs in cord blood
DNA and birth weight. We identiﬁed associations in 9 genes,
2 of which (ARID5B (2 CpGs) and XRCC3 (4 CpGs)) had
multiple signiﬁcant CpGs. This is one of the ﬁrst studies to
examine DNA methylation across the genome in relation to
birth weight and the ﬁrst to have used the 450K platform.
Additionally, our use of a large, well-deﬁned birth cohort
provides essential covariate data to adjust for confounders
of the methylation–birth weight relationships.
We found an inverse association between ARID5Bmethyl-
ation and birth weight (higher methylation fraction associated
with lower birth weight) (Figure 1). ARID5B (also known as
MRF2/MRF-2), is a transcriptional coactivator that plays a key
role in adipogenesis. ARID5B knockout mice have a high rate of
neonatal death and reduced lipid accumulation, whichmanifests
in signiﬁcantly lower weight from postnatal day 5 onward (34).
Both full and partial ARID5B knockouts are resistant to weight
gain and obesity, even after high-fat dietary challenges (34).
One possible mechanism explaining these ﬁndings is the mod-
ulation of leptin levels, given that down-regulation of ARID5B
results in increased expression of leptin, an important regulator
of energy balance, insulin resistance, and metabolism (35).
Table 2. Associations of Selected CpGsa and Infant Birth Weight in the Norwegian Mother and Child Cohort Study, 1999–2008
CpG by Birth
Weight Difference Gene
Adjusted Mean Difference
in Birth Weight (SE)b
Bonferroni-Corrected
P Valuec
Adjusted Mean Difference
in Birth Weight (SE)d
Bonferroni-Corrected
P Valuec
Decrease in birth
weight
cg25953130 ARID5B −371.26 (58.11) 8.11 × 10−5 −376.86 (53.93) 1.35 × 10−6
cg08005122 −493.38 (83.70) 1.82 × 10−3 −345.57 (74.14) 1.00
cg20076442 −302.79 (51.62) 2.17 × 10−3 −304.93 (47.00) 4.22 × 10−5
cg02863179 ARID5B −340.99 (59.30) 4.33 × 10−3 −340.46 (51.76) 2.32 × 10−5
cg25124943 −480.24 (89.53) 3.96 × 10−2 −402.67 (77.99) 0.12
cg00049440 KLF9 −314.29 (58.69) 4.14 × 10−2 −302.06 (61.59) 0.45
Increase in birth
weight
cg02194129 XRCC3 726.57 (96.34) 2.24 × 10−8 403.00 (81.84) 0.41
cg17836177 PEBP4 558.39 (93.08) 9.61 × 10−4 481.80 (78.73) 4.56 × 10−4
cg12798040 XRCC3 326.29 (54.73) 1.21 × 10−3 268.26 (53.75) 0.29
cg00605777 SEMA4C 728.27 (122.89) 1.50 × 10−3 234.27 (83.10) 1.00
cg14172849 XRCC3 660.38 (112.59) 2.17 × 10−3 271.75 (76.66) 1.00
cg23127323 SPON2 323.05 (56.72) 5.97 × 10−3 257.23 (43.93) 2.31 × 10−3
cg25162533 382.67 (68.28) 1.01 × 10−2 371.26 (65.87) 8.40 × 10−3
cg23369670 XRCC3 557.29 (99.73) 1.12 × 10−2 144.55 (66.65) 1.00
cg17714703 UHRF1 296.96 (54.11) 1.97 × 10−2 322.68 (47.99) 8.64 × 10−6
cg08420923 ANKRD11 493.22 (91.53) 3.45 × 10−2 457.16 (75.05) 5.44 × 10−4
cg23237276 523.19 (97.67) 4.12 × 10−2 382.82 (73.05) 0.08
cg05993265 MFSD10 442.00 (82.59) 4.23 × 10−2 236.24 (67.26) 1.00
cg24693803 538.69 (101.12) 4.84 × 10−2 457.97 (88.27) 0.10
Abbreviations: ANKRD11, ankyrin repeat domain 11; ARID5B, AT-rich interaction domain 5B (MRF1-like); CpG, cytosine-guanine dinucleotide;
KLF9, Kruppel-like factor 9;MFSD10, major facilitator superfamily domain containing 10; PEBP4, phosphatidylethanolamine-binding protein 4; SE,
standard error; SEMA4C, sema domain, immunoglobulin domain, transmembrane domain, and short cytoplasmic domain, (semaphorin) 4C;
SPON2, spondin 2, extracellular protein; UHRF1, ubiquitin-like with PHD and ring finger domains 1; XRCC3, x-ray repair complementing
defective repair in Chinese hamster cells 3.
a From Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, California).
b Per logit increase in methylation fraction, including covariates for child sex, maternal plasma cotinine, parity, maternal age, dietary folate not
including supplements, asthma, gestational age at delivery, gestational age at delivery squared, preeclampsia, season of birth, and leukocyte cell–
type proportions.
c Unadjusted P values multiplied by 485,492 (number of tests). The threshold for significance remains P < 0.05 (5 × 10−2).
d Per logit increase in methylation fraction, including covariates for factors listed above with leukocyte cell–type proportion removed.
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The ARID5B CpGs associated with birth weight in our
study are located in the gene body, which typically results
in enhanced expression (4–6). However, using gene expres-
sion and methylation data from 41 normal breast tissue sam-
ples in The Cancer Genome Atlas (http://cancergenome.nih.
gov), we observed an inverse relationship between methyla-
tion at the 2 signiﬁcant CpGs in the ARID5B gene and
ARID5B expression. Although the effect size was large, the
correlation was not statistically signiﬁcant (P = 0.15). Thus,
further systematic functional studies are required to describe
the relationship between methylation at this site and ARID5B
gene expression in cord blood samples. Of potential interest,
polymorphisms in the ARID5B gene have been associated
with increased risk for acute lymphoblastic leukemia (36,
37), coronary artery disease (38), and type 2 diabetes (39).
XRCC3 is a critical DNA repair gene, whose function dur-
ing development is ensuring the accurate duplication of cells
through homologous recombination (40, 41). In XRCC3-
deﬁcient hamster cell lines, repair of DNA double-strand
breaks is decreased 25-fold (41). Infante-Rivard et al. (42)
examined a coding polymorphism (Thr241Met) in XRCC3
in relation to small for gestational age and found no overall
increased risk of small for gestational age related to genotype,
althoughwomenwho smoked in the third trimester and carried
the variant that encodes threonine were at somewhat increased
risk of having offspring that were small for gestational age.
However, there are no other studies that have reported an as-
sociation of XRCC3 with any fetal growth parameter. In our
study, 4 XRCC3 CpGs were associated with increased birth
weight, suggesting an inverse correlation between XRCC3
expression (via increased methylation) and birth weight.
However, these associations were signiﬁcant only in models
adjusted for peripheral blood leukocyte cell–type proportion
and, thus, require more research to fully understand.
Other genes highlighted in our study have been shown to
be important in developmental processes, although their rela-
tion to fetal growth in particular has not been addressed.
UHRF1 has multiple domains that bind chromatin and has
been shown to be important in the maintenance of DNAmeth-
ylation (43). In mice, UHRF1 is highly expressed in pluripo-
tent stem cells, as opposed to differentiated tissue (44), and
genetic ablation of UHRF1 has been shown to result in geno-
mic hypomethylation (45, 46). Yippee-like 3 (Drosophila)
(YPEL3) is regulated by p53 and induces cellular senescence.
It has growth-inhibitory effects in both normal and tumor cell
lines (47). In our data, increased methylation (presumably
negatively regulating gene expression) was associated with
increased birth weight, which would represent a logically
consistent direction of association. ANKRD11 enhances the
transcriptional activity of p53 (48) and is of increasing
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Figure 1. Cytosine-guanine dinucleotide methylation β values for significant AT-rich interactive domain 5B (MRF1-like) (ARID5B) probes in rela-
tion to birth weight residual in the Norwegian Mother and Child Cohort Study, 1999–2008. Untransformed methylation β values for ARID5B
A) cg25953130 (P = 8.11 × 10−5) and B) cg02863179 (P = 4.33 × 10−3) are plotted against the birth weight residual after adjustment for child sex,
maternal plasma cotinine, parity, maternal age, dietary folate not including supplements, asthma, gestational age at delivery, gestational age at
delivery squared, preeclampsia, season of birth, and leukocyte cell–type proportions. Methylation β values were divided into 8 equally spaced in-
tervals. Both show a roughly linearly declining trend in birth weight with increasing methylation fraction.
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interest in relation to autism (49). Mutations in ANKRD11 are
associated with KBG syndrome, a rare genetic disease char-
acterized by short stature, typical facial dysmorphism, dental
issues, and developmental delay (50). In KBG syndrome,
birth weight is typically normal but birth length is often below
the third percentile.
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Figure 2. Cytosine-guanine dinucleotide methylation β values for significant x-ray repair complementing defective repair in Chinese hamster cells
3 (XRCC3) probes in relation to birth weight residual. Untransformed methylation β values of XRCC3 A) cg02194129 (P = 2.24 × 10−8),
B) cg12798040 (P = 1.21 × 10−3), and C) cg14172849 (P = 2.17 × 10−3) are plotted against the birth weight residual after adjustment for child
sex, maternal plasma cotinine, parity, maternal age, dietary folate not including supplements, asthma, gestational age at delivery, gestational
age at delivery squared, preeclampsia, season of birth, and leukocyte cell–type proportions. Methylation β values were divided into 8 equally spaced
intervals. All show a roughly linearly increasing trend in birth weight with increasing methylation fraction.
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Genes are turned on and off dynamically during develop-
ment (51); thus, methylation, as a means of controlling gene
expression and the activation of biological cascades, is im-
portant for fetal development and parturition. However, in
the current and previous studies (17, 18, 52, 53), methylation
status is measured only once (at delivery), and therefore may
not always generalize to antecedent periods or to births that
occur remote from term. Indeed, all studies of cord blood
methylation and birth outcomes are, by their nature, cross-
sectional (i.e., exposure (methylation) and outcome (birth
weight) are measured simultaneously). The methylation sta-
tus of cord blood CpGs may be the consequence of exposures
experienced during pregnancy that result in changes in the
timing of delivery or growth of the fetus, or alternatively, it
may reﬂect the developmental process ongoing at the time
of delivery. Because of the temporal uncertainty and inﬂu-
ence of other factors on cord blood methylation patterns, we
have presented our results as associations without making
strong causal arguments.
The strengths of our study are many. First, we used the Il-
lumina 450K technology, which provides state-of-the-art
epigenome-wide coverage. Second, our study was nested
within MoBa, a population-based cohort of Norwegian women
recruited early in pregnancy. The MoBa cohort is racially ho-
mogeneous, which is beneﬁcial in the setting of birth weight
analyses given the strong and consistent racial disparities in
mean birth weight across the spectrum of gestational age
(47). Norwegians also have nationalized health care, ensuring
the adequacy of free antenatal care across the socioeconomic
spectrum. These beneﬁcial characteristics of MoBa would
tend to reduce the likelihood of residual confounding by any
unmeasured factors associated with race and access to care.
A signiﬁcant strength of our study is that we were able to
adjust for strong known correlates of birth weight (such as
prenatal smoking, as measured by plasma cotinine levels in
the second trimester), parity, maternal age, and other factors
associated with the probability of selection into this nested
study. Although the original study was sampled to over-
represent asthma cases at 3 years, our results adjusted for this
selection factor and were found to be robust on the basis of
analyses of only the random subcohort (data not shown).
Moreover, ours is the largest study to date to examine cord
blood methylation in relation to birth weight. We observed
somewhat different associations when we adjusted for esti-
mated leukocyte cell–type proportions, which have been
shown to exhibit important variation in methylation proﬁles
(31, 32). However, it is not yet clear how appropriate these
methods are in the setting of cord blood. For example, cord
blood contains more nucleated red blood cells than does adult
blood, and these might vary by gestational age, although the
percentage of nucleated red blood cells of all nucleated cells
remains low in cord blood (3.2%) (54). Further research ex-
amining variability in cord blood cell population methylation
proﬁles is required.
In conclusion, using cord blood DNA, we identiﬁed a small
number of CpGs in 9 genes, including multiple signiﬁcant
CpGs in ARID5B and XRCC3, which are associated with
birthweight in a large population-based cohort. Some biological
plausibility for a role for ARID5B in particular in fetal growth
is provided by associations with postnatal growth and lipid
accumulation in mice. The other genes have been less well
studied, but many are involved in developmental processes.
Although the underlying mechanism and associated causal
processes are unclear, these ﬁndings may provide novel in-
sights into the role of epigenetic modiﬁcations, including
methylation, in the regulation of fetal growth and parturition.
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